Search clinical trials for: nighttime dosing of mirabegron

Total 1693 results

Far Eastern Memorial Hospital

Recruiting

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Overactive Bladder Syndrome

Taiwan
The Affiliated Ganzhou Hospital of Nanchang University

Active, not recruiting

Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)

Overactive Bladder

China
Massachusetts General Hospital

Recruiting

The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU

Sleep | Glucose Intolerance | Feeding Patterns

United States
Children's Hospital of Philadelphia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

CBF and Childhood OSAS

Obstructive Sleep Apnea Syndrome

United States
Genuine Research Center, Egypt
Multi-Apex Pharma

Completed

Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

Healthy

Egypt
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
Astellas Pharma Inc

Completed

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Healthy Subjects | Bioavailability | Pharmacokinetics of Mirabegron

Netherlands
Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
Peking Union Medical College Hospital

Not yet recruiting

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Overactive Bladder
Far Eastern Memorial Hospital

Recruiting

Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Female Patients With Overactive Bladder Syndrome

Taiwan
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
Columbia University
University of Copenhagen; HIAS

Active, not recruiting

Feasibility of Community Psychosocial Intervention for Women

Stress | Psychological Distress | Mental Health Wellness 1 | Coping Skills

Ecuador, Panama
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Parc de Salut Mar

Completed

Prevalence of Sialorrhea in Patients Treated With Clozapine

Quality of Life | Sialorrhea | Clozapine Adverse Reaction

Spain
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Far Eastern Memorial Hospital

Withdrawn

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Seoul National University Hospital

Unknown

MIrabegron With oveRACtive bLadder Symptoms in mEn

Overactive Bladder

Korea, Republic of
Astellas Pharma Inc

Completed

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Samsung Medical Center

Completed

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Overactive Bladder

Korea, Republic of
University of Washington
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Feasibility Trial Using an Inpatient Insulin Dosing Calculator

Diabetes Mellitus, Type 2
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Astellas Pharma Inc

Completed

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Overactive Bladder | Pharmacokinetics

France
Astellas Pharma Inc

Completed

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Healthy Subjects | Pharmacokinetics

Netherlands
Tianjin Medical University General Hospital

Recruiting

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Intracerebral Haemorrhage

China
University of Alabama at Birmingham

Completed

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study) (PTNS-M)

Overactive Bladder

United States
University Hospitals Cleveland Medical Center

Withdrawn

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)

Overactive Bladder | Neurogenic Detrusor Overactivity

Denmark, Poland
Catalan Institute of Health

Completed

Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron

Overactive Bladder Syndrome
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity

Neurogenic Detrusor Overactivity

Philippines, Turkey, Belgium, Denmark
Chang Gung Memorial Hospital

Completed

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB Symptoms

Urinary Bladder, Overactive | Sexual Behavior | Sexual Function Disturbances | Behavior Therapy | Sexual Activity

Taiwan
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Metabolic Processes

Netherlands
Armed Forces Institute of Dentistry, Pakistan

Completed

Comparison of Different Methods of Controlling Pain During Debonding of Orthodontic Brackets

Analgesia | Orthodontic Appliance Complication

Pakistan
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Brown Fat Activation Study

Metabolic Syndrome | Obese

United States
Centro Hospitalar do Tâmega e Sousa

Completed

Inflammatory Parameters as Predictive Factors for Complicated Appendicitis

Acute Appendicitis
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.

United Kingdom, United States

Search clinical trials for: nighttime dosing of mirabegron

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations